We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+2.16%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$996M
AUM Growth
-$456M
Cap. Flow
-$261M
Cap. Flow %
-26.18%
Top 10 Hldgs %
67.37%
Holding
55
New
1
Increased
2
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$3.17M
2
RZLT icon
Rezolute
RZLT
+$1.63M
3
GTH
Genetron Holdings Limited ADS
GTH
+$1.22M

Top Sells

Rank Stock Value
1
NFH
New Frontier Health Corporation Ordinary Shares
NFH
+$171M
2
ASND icon
Ascendis Pharma A/S
ASND
+$27.9M
3
HRMY icon
Harmony Biosciences
HRMY
+$21.4M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$15M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.84%
2 Materials 2.16%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLU
26
DELISTED
BELLUS Health Inc.
BLU
$9.4M 0.94%
1,017,152
– –
VERA icon
27
Vera Therapeutics
VERA
$2.3B
$9.07M 0.91%
666,666
– –
BOLT icon
28
Bolt Biotherapeutics
BOLT
$7.67M
$7.9M 0.79%
193,565
– –
IOVA icon
29
Iovance Biotherapeutics
IOVA
$1.82B
$7.23M 0.73%
655,057
– –
AVDL
30
DELISTED
Avadel Pharmaceuticals
AVDL
$7.17M 0.72%
2,937,093
– –
OLMA icon
31
Olema Pharmaceuticals
OLMA
$1B
$6.88M 0.69%
1,689,515
– –
DSGN icon
32
Design Therapeutics
DSGN
$761M
$6.67M 0.67%
476,589
– –
TERN
33
DELISTED
Terns Pharmaceuticals
TERN
$6.63M 0.67%
2,675,133
– –
WHWK
34
Whitehawk Therapeutics
WHWK
$190M
$6.28M 0.63%
509,572
-262,844
-34% -$3.9M
CMPX icon
35
Compass Therapeutics
CMPX
$344M
$5.3M 0.53%
2,000,000
– –
GRCL
36
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$5.29M 0.53%
961,359
– –
UTRS
37
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$5.21M 0.52%
110,783
– –
STSA
38
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$5.1M 0.51%
1,232,394
– –
ARWR icon
39
Arrowhead Research
ARWR
$11.9B
$4.84M 0.49%
137,411
– –
ALGS icon
40
Aligos Therapeutics
ALGS
$26.2M
$4.29M 0.43%
141,881
– –
CDXS icon
41
Codexis
CDXS
$151M
$4.06M 0.41%
388,144
– –
DYN icon
42
Dyne Therapeutics
DYN
$4.7B
$3.97M 0.4%
577,642
– –
SERA icon
43
Sera Prognostics
SERA
$79.9M
$3.04M 0.31%
1,856,011
– –
RZLT icon
44
Rezolute
RZLT
$454M
$1.58M 0.16%
+489,473
New +$1.63M
ZYME icon
45
Zymeworks
ZYME
$1.61B
$1.52M 0.15%
286,064
– –
ASLN
46
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.41M 0.14%
71,023
– –
QTTB icon
47
Q32 Bio
QTTB
$466M
$729K 0.07%
20,559
-26,838
-57% -$916K
DTIL icon
48
Precision BioSciences
DTIL
$180M
$224K 0.02%
4,675
– –
MTCR
49
DELISTED
Metacrine, Inc. Common Stock
MTCR
$73K 0.01%
146,426
– –
ELEV
50
DELISTED
Elevation Oncology
ELEV
– –
-496,844
Closed -$1.25M
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Vivo Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Vivo Capital held 55 positions worth $996M, down 31% from $1.45B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Vivo Capital withdrew a net $261M in Q2 2022, closing 6 positions and reducing 8 holdings. Its most notable exit was New Frontier Health Corporation Ordinary Shares, an estimated $171M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 85% a quarter earlier, followed by Materials and Financials.

Against the trend, Vivo Capital opened a new position in Rezolute worth $1.58M.

  • Vivo Capital's largest Q2 2022 buy was Rezolute: 489,473 shares worth $1.58M.
  • Vivo Capital added most to Zai Lab in Q2 2022, an estimated $3.17M increase.
  • Vivo Capital's biggest Q2 2022 reduction was Ascendis Pharma A/S, cutting an estimated $27.9M.
  • Vivo Capital fully exited New Frontier Health Corporation Ordinary Shares in Q2 2022, selling an estimated $171M.
  • Vivo Capital's ten largest holdings make up 67% of its $996M portfolio in Q2 2022.
  • Vivo Capital opened 1 new position and closed 6 in Q2 2022.
  • Vivo Capital's portfolio value fell 31% quarter-over-quarter to $996M.

Based on Vivo Capital's 13F filing for Q2 2022, filed 15 Aug 2022.